Human VEGF (Bevacizumab Biosimilar) Antibody Summary
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Cell Proliferation Induced by VEGF165 and Neutralization by Human VEGF (Bevacizumab Biosimilar) Antibody. Recombinant Human VEGF165 (Catalog # 293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line) as measured by Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Human VEGF165 (10 ng/mL) is neutralized (green line) by increasing concentrations of Human Anti-Human VEGF (Bevacizumab Biosimilar) Monoclonal Antibody (Catalog # MAB9947). The ND50 is typically 10-80 ng/mL.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 degreesC, as supplied. 1 month, 2 to 8 degreesC under sterile conditions after opening. 6 months, -20 to -70 degreesC under sterile conditions after opening.
Bevacizumab is a biosimilar directed against VEGF.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human VEGF (Bevacizumab Biosimilar) Antibody
There are currently no reviews for this product. Be the first to review Human VEGF (Bevacizumab Biosimilar) Antibody and earn rewards!
Have you used Human VEGF (Bevacizumab Biosimilar) Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image